24/7 Market News Snapshot 21 October, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

October 21, 2025

DENVER, Colo., 21 October, 2025 (www.247marketnews.com) – (NASDAQ:PSTV) are discussed in this article.
PLUS THERAPEUTICS, Inc. (PSTV), a clinical-stage pharmaceutical company dedicated to advancing treatment options for central nervous system (CNS) cancers, is currently experiencing a robust rise in its stock, marked by a pre-market trading price of $0.678, representing an increase of 17.04% from the previous day’s close of $0.579. Enhanced trading volume of 6.03 million shares underscores a strong investor interest, signaling potential upward momentum. Key resistance levels are identified around $0.70, with support noted at $0.65, suggesting that monitoring these thresholds alongside market sentiment is critical for informed trading decisions.

In addition to its market performance, PLUS THERAPEUTICS is making significant operational strides. The company’s wholly-owned subsidiary, CNSide Diagnostic LLC, is advancing its preparedness for commercial operations, recently achieving CLIA certification for its innovative Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory-developed test (LDT). This development is a critical step in addressing pressing medical needs in CNS cancer diagnostics.

To further bolster its operational capacity, PLUS THERAPEUTICS has announced key leadership changes, promoting Russ Havranek, MS, MBA, to Executive Vice President of Commercial and Corporate Strategy, and Daniel Ortega, MBA, to Vice President of Development and Technical Operations. These appointments are anticipated to enhance the company’s diagnostic capabilities, fostering its commitment to delivering patient-centered innovation.

Moreover, a strategic policy agreement with UnitedHealthcare will extend coverage of CNSide’s offerings to over 51 million individuals, reflecting the company’s growth trajectory and its goal of making cutting-edge diagnostics more accessible. With a new state-of-the-art manufacturing facility now secured, PLUS THERAPEUTICS is well equipped to meet anticipated demand and strengthen its partnerships with leading medical institutions. As the company pursues these strategic initiatives, its dedication to improving patient outcomes in CNS cancer remains paramount.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.